Best mid-cap healthcare stocks to invest in 2026

Mid-cap healthcare blends innovation with scalability, offering investors exposure to diverse medical advances. These companies expand access, improve outcomes, and compound growth through focused execution.

Krystal Biotech commercializes gene therapies for rare skin diseases using its HSV-1 platform, advancing patient care with validated, scalable genetic medicine. Telix Pharmaceuticals develops radiopharmaceuticals that diagnose and treat cancer with targeted precision, pairing imaging agents with therapeutic delivery. LeMaitre Vascular specializes in medical devices for vascular disease treatment, offering innovative solutions for peripheral vascular conditions with global market presence.

These mid-cap healthcare leaders combine disciplined execution with durable growth potential. These are among the best mid-cap healthcare stocks for 2026.

Roboforex R-Trader gives you access to over 10,000 stocks, ETFs, commodities, and crypto. All of the stocks mentioned in this article are available for purchase there.

Before we dive into each company, let`s take a look at how your investment would have performed if you had invested in stocks mentioned in this article.

Now, let`s take a closer look at each of the companies:

  • Krystal Biotech (NYSE:KRYS)

    Krystal Biotech is a biotechnology company focused on developing innovative gene therapy treatments for rare and serious skin diseases using its proprietary HSV-1-based platform. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company specializes in creating genetic medicines that address unmet medical needs in dermatology and respiratory ailments. Krystal Biotech is dedicated to advancing genetic medicine with a strong emphasis on breakthrough therapies for patients with limited treatment options.

    The company`s lead product, Vyjuvek, is an FDA-approved gene therapy designed to treat dystrophic epidermolysis bullosa (DEB), a rare and debilitating skin disorder. Krystal Biotech`s expanding pipeline includes other gene therapies targeting additional dermatological and respiratory conditions, demonstrating its commitment to expanding the applications of genetic medicine. By integrating cutting-edge science with a patient-centric approach, Krystal Biotech continues to push the boundaries of innovation in gene therapy.

    Krystal Biotech financial statements

    Analysts recommendation: 1.17

    Financial Health

    • Return on assets (ROA): 8.44%
    • Return on equity (ROE): 18.91%
    • Return on investment (ROI): 17.36%

    Profitability

    • Gross margin: 94.08%
    • Operating margin: 41.33%
    • Net profit margin: 52.64%

    Growth

    • EPS (past 5 years): N/A
    • EPS (current): 6.67
    • EPS estimate (next quarter): 1.5
    • EPS growth (this year): 11.6%
    • EPS growth (next year): 21.3%
    • EPS growth (next 5 years): 49.8%
    • EPS growth (quarter-over-quarter): 192.66%
    • Sales growth (past 5 years): N/A
    • Sales growth (quarter-over-quarter): 17.5%

    💡 Why invest in Krystal Biotech?

    Krystal Biotech offers unique strengths for investors seeking exposure to innovative biotech companies with high growth potential:

    • FDA Approval Success: Krystal Biotech achieved FDA approval for Vyjuvek, the first gene therapy for dystrophic epidermolysis bullosa, generating substantial revenue streams and validating their HSV-1 delivery platform for future applications.
    • Orphan Drug Positioning: The company strategically targets rare skin diseases with substantial unmet medical needs, securing orphan drug designations that provide market exclusivity, premium pricing, and reduced regulatory pathways.
    • Proprietary Platform Edge: Krystal`s HSV-1-based gene delivery system enables multiple therapeutic applications across dermatological and respiratory conditions, creating substantial pipeline expansion opportunities and long-term growth potential.
    • Strong Financial Metrics: The company demonstrates impressive profitability with high gross margins and strong cash generation capabilities, providing financial stability and resources for continued research and development investments.

    🐌 Key considerations before investing in Krystal Biotech

    Krystal Biotech faces notable challenges that could impact its long-term success despite promising developments in gene therapy:

    • Development Risk Factors: Gene therapy development involves complex manufacturing processes, potential safety concerns, and uncertain clinical outcomes that could delay or prevent successful commercialization of pipeline candidates.
    • Market Size Constraints: Rare disease markets have inherently small patient populations, limiting revenue potential and requiring premium pricing strategies that may face significant reimbursement challenges from healthcare systems.
    • Competitive Pressure Threats: Large pharmaceutical companies and specialized biotechnology firms increasingly compete in gene therapy markets, potentially challenging Krystal`s market position, pricing power, and long-term competitive advantages.
    • Regulatory Oversight Burden: Gene therapies face stringent regulatory oversight and evolving safety requirements that can significantly increase development costs, extend approval timelines, and create substantial compliance challenges.

    Final thoughts on Krystal Biotech

    Krystal Biotech's FDA-approved Vyjuvek and strong profitability metrics demonstrate successful execution in the rare disease gene therapy space, positioning the company for sustained growth. Its proprietary HSV-1 delivery platform and strategic orphan disease focus offer durable competitive advantages in the evolving genetic medicine market. Investors should carefully consider development risks, reimbursement challenges, and competitive pressures inherent to emerging gene therapy technologies before making investment decisions.

  • Telix Pharmaceuticals (AX:TLX)

    Telix Pharmaceuticals specializes in the development of radiopharmaceuticals, which are drugs that use radioactive isotopes to diagnose and treat serious diseases, primarily in oncology. Founded in 2015 and headquartered in Melbourne, Australia, the company has expanded globally with operations across key markets, establishing leadership in precision medicine. Since its founding, Telix has demonstrated strong growth in the theranostics market by combining diagnostic imaging with targeted radiation therapy.

    Telix develops targeted radiation therapies for cancers including prostate, kidney, and brain tumors, using molecularly targeted radiation to locate and destroy cancer cells. The company`s flagship product, Illuccix, is an advanced imaging agent for prostate cancer detection and has received regulatory approval in multiple countries. In addition to commercial products, Telix maintains a strong pipeline of investigational therapies aimed at revolutionizing cancer treatment through innovative imaging and therapeutic solutions.

    Telix Pharmaceuticals financial statements

    Analysts recommendation: 1.29

    Financial Health

    • Return on assets (ROA): 2.08%
    • Return on equity (ROE): 3.14%
    • Return on investment (ROI): 1.36%

    Profitability

    • Gross margin: 53.94%
    • Operating margin: -0.3%
    • Net profit margin: 1.63%

    Growth

    • EPS (past 5 years): N/A
    • EPS (current): 0.03
    • EPS estimate (next quarter): 0.23
    • EPS growth (this year): -32.63%
    • EPS growth (next year): 206.46%
    • EPS growth (next 5 years): 42.88%
    • EPS growth (quarter-over-quarter): N/A
    • Sales growth (past 5 years): 192.28%
    • Sales growth (quarter-over-quarter): 58.9%

    💡 Why invest in Telix Pharmaceuticals?

    Telix Pharmaceuticals shows compelling qualities that make it stand out in its sector for potential long-term investors:

    • Theranostic Market Leadership: Telix pioneers the rapidly growing theranostics market, combining diagnostic imaging with targeted radiation therapy to create personalized cancer treatments with significant competitive advantages in oncology.
    • Illuccix Commercial Success: The company`s flagship product Illuccix achieved regulatory approval in multiple countries for prostate cancer imaging, generating substantial revenue and validating their technology platform for future.
    • Diversified Pipeline Strategy: Telix develops radiopharmaceuticals for various cancer types including prostate, kidney, and brain tumors, reducing dependency on single products while expanding addressable market opportunities in oncology.
    • Global Operations Reach: With operations across Australia, North America, Europe, and Asia-Pacific, Telix accesses diverse patient populations and multiple regulatory pathways for accelerated market penetration and growth worldwide.

    🐌 Key considerations before investing in Telix Pharmaceuticals

    Telix Pharmaceuticals faces challenges that could impact long-term success despite promising developments in radiopharmaceuticals:

    • Clinical Development Risks: Most of Telix`s pipeline candidates remain in clinical development, creating substantial uncertainty around regulatory approval timelines, efficacy outcomes, and commercialization success rates for future products.
    • Competitive Market Threats: The theranostics sector attracts pharmaceutical giants and biotechnology companies, intensifying competition for market share, talent acquisition, and strategic partnership opportunities globally across oncology markets.
    • Reimbursement Policy Challenges: Novel radiopharmaceuticals face complex reimbursement negotiations with healthcare systems and insurers, potentially limiting patient access and affecting revenue generation capabilities for treatments in key markets.
    • Manufacturing Compliance Burden: Radiopharmaceuticals require specialized manufacturing facilities and stringent regulatory oversight, creating significant operational challenges and increasing compliance costs across jurisdictions worldwide.

    Final thoughts on Telix Pharmaceuticals

    Telix Pharmaceuticals' leadership in theranostic medicine and commercial progress with Illuccix highlight its ability to translate innovation into viable cancer care solutions for patients worldwide. A diversified pipeline and global footprint provide multiple paths for sustained growth in precision oncology markets across different geographic regions. Investors should carefully weigh development risks, reimbursement policy challenges, and regulatory complexities when considering a potential investment in Telix Pharmaceuticals.

  • LeMaitre Vascular (NYSE:LMAT)

    LeMaitre Vascular is a medical device company specializing in products for the treatment of vascular disease with a focus on peripheral vascular conditions. Founded in 1983 and headquartered in Burlington, Massachusetts, the company develops and manufactures innovative solutions for surgeons treating complex vascular conditions worldwide. LeMaitre Vascular serves a global market, offering a comprehensive range of devices designed to improve patient outcomes in vascular surgery procedures.

    The company`s product portfolio includes grafts, stents, balloons, patches, and biologic implants used in procedures such as bypass surgery and vessel repair. With a strong emphasis on research and development, LeMaitre Vascular continually expands its offerings through strategic acquisitions and in-house innovation. By maintaining close surgeon relationships and investing in cutting-edge medical technologies, the company remains a leader in the field of vascular surgery solutions worldwide.

    LeMaitre Vascular financial statements

    Analysts recommendation: 2

    Financial Health

    • Return on assets (ROA): 7.94%
    • Return on equity (ROE): 15.02%
    • Return on investment (ROI): 8.63%

    Profitability

    • Gross margin: 70.97%
    • Operating margin: 25.41%
    • Net profit margin: 22.14%

    Growth

    • EPS (past 5 years): 16.99%
    • EPS (current): 2.32
    • EPS estimate (next quarter): 0.57
    • EPS growth (this year): 53.6%
    • EPS growth (next year): 8.94%
    • EPS growth (next 5 years): 12.77%
    • EPS growth (quarter-over-quarter): 15.66%
    • Sales growth (past 5 years): 13.4%
    • Sales growth (quarter-over-quarter): 11.4%

    💡 Why invest in LeMaitre Vascular?

    LeMaitre Vascular presents compelling fundamentals that position it well for investors seeking stable returns and growth prospects:

    • Vascular Device Leadership: LeMaitre boasts a legendary pedigree in peripheral vascular devices, specializing in innovative solutions for treating blockages and improving blood flow to the legs and feet with consistent demand across global markets.
    • Strategic Product Diversification: Recognizing the diverse needs of vascular patients, LeMaitre expands its offerings through minimally invasive stents, vein closure systems, and advanced diagnostic tools to drive sustainable growth.
    • R&D Innovation Investment: From biocompatible materials to AI-powered procedural guidance, LeMaitre invests heavily in research and development to stay ahead with solutions that redefine vascular interventions globally for future growth.
    • Global Market Presence: With operations spanning continents, LeMaitre caters to diverse vascular needs worldwide, unlocking significant international growth potential in emerging markets with aging populations and chronic disease prevalence.

    🐌 Key considerations before investing in LeMaitre Vascular

    However, LeMaitre Vascular faces headwinds that could impact future performance and investment returns for careful consideration:

    • Stock Valuation Concerns: Like many established medical device companies, LeMaitre`s stock can be volatile, and the current price might reflect expectations of future regulatory approvals and clinical trial outcomes for long-term investors.
    • Regulatory Approval Headwinds: Evolving regulations surrounding medical device approvals and reimbursement policies can significantly impact LeMaitre`s market access and profitability across multiple jurisdictions worldwide in the coming years.
    • Competitive Market Pressure: Larger established players and nimble start-ups are aggressively vying for market share in the vascular space, challenging LeMaitre`s competitive edge in the medical device industry worldwide with innovative solutions.
    • Healthcare Policy Uncertainty: Macroeconomic factors like healthcare reforms and insurance coverage changes can significantly impact patient access to treatment and indirectly affect LeMaitre`s sales across global healthcare markets.

    Final thoughts on LeMaitre Vascular

    LeMaitre Vascular`s leadership in vascular devices, product offerings, and global market presence paint a promising picture for long-term investors seeking medical device sector exposure. However, the volatile nature of the stock, regulatory headwinds from evolving policies, and intensifying competition from larger players warrant a measured approach to investment decisions. For investors willing to conduct thorough research properly, LeMaitre Vascular represents an interesting opportunity in the growing vascular healthcare market.

  • Hims & Hers Health (NYSE:HIMS)

    Hims & Hers Health Inc. is a direct-to-consumer telehealth company offering personalized healthcare solutions through a comprehensive digital platform for consumers. Founded in 2017 and headquartered in San Francisco, California, the company has rapidly expanded its services across the United States with innovative virtual care offerings. The company achieved its first profitable year recently, reporting significant revenue growth and net income demonstrating strong business model execution across its digital platform nationwide.

    The company`s core business encompasses several key segments including men`s health, women`s health, mental health services, dermatology, and weight management solutions. Hims & Hers operates a subscription-based model, providing virtual consultations, prescription medications, and over-the-counter products delivered directly to consumers nationwide. The company leverages its established digital infrastructure to serve a broader patient population across diverse medical needs while expanding into additional healthcare categories.

    Hims & Hers Health financial statements

    Analysts recommendation: 2.78

    Financial Health

    • Return on assets (ROA): 5.54%
    • Return on equity (ROE): 26.21%
    • Return on investment (ROI): 7.89%

    Profitability

    • Gross margin: 75.01%
    • Operating margin: 1.97%
    • Net profit margin: 6.05%

    Growth

    • EPS (past 5 years): 17.22%
    • EPS (current): 0.53
    • EPS estimate (next quarter): 0.04
    • EPS growth (this year): -80.3%
    • EPS growth (next year): 31.83%
    • EPS growth (next 5 years): 14.91%
    • EPS growth (quarter-over-quarter): -80.29%
    • Sales growth (past 5 years): N/A
    • Sales growth (quarter-over-quarter): 49.2%

    💡 Why invest in Hims & Hers Health?

    Hims & Hers Health presents fundamental strengths for investors seeking exposure to digital healthcare transformation opportunities:

    • Strong Revenue Expansion: The company posted significant revenue growth recently, reflecting strong product-market fit, efficient marketing spend, and rising brand recognition as consumers embrace convenient virtual care nationwide.
    • Profitable Year Achievement: Delivering net income on substantial revenue shows Hims & Hers can reach scale economics while investing heavily in technology infrastructure, clinical capacity, and new service development for future growth.
    • Growing Subscriber Base: With a large and growing subscriber base, the platform gains deeper customer cohorts, richer engagement data, and an expanded foundation for cross-selling healthcare offerings profitably across markets worldwide.
    • Diversified Service Lineup: A broad menu across men`s and women`s health, dermatology, mental health, and weight-management reduces reliance on any single category and supports sustainable long-term growth trajectory in healthcare industry.

    🐌 Key considerations before investing in Hims & Hers Health

    However, investors should consider the challenges facing Hims & Hers Health in its competitive telehealth market landscape:

    • Regulatory Compliance Burden: Compounded weight-loss treatments, evolving telehealth regulations, and differing state-level requirements draw scrutiny from regulators and could restrict offerings, increasing compliance costs across operations.
    • Intense Market Competition: Telehealth rivals, traditional healthcare providers, and digital pharmacies aggressively compete for similar patients, increasing acquisition costs and raising the bar for clinical quality standards in the market.
    • Subscription Volatility Risk: Dependence on subscription revenue exposes results to customer churn and pricing sensitivity, requiring continuous product refresh and personalized engagement to sustain lifetime customer economics profitably.
    • Brand Perception Concern: Executive stock sales, debate over compounded medications, and scrutiny of direct-to-consumer health marketing can influence public perception and regulatory posture toward the company in healthcare markets.

    Final thoughts on Hims & Hers Health

    Hims & Hers Health`s rapid revenue expansion, achieving profitability milestone, and growing subscriber base underscore its potential as a scaled direct-to-consumer telehealth platform for investors. At the same time, regulatory scrutiny, competitive intensity, and subscription-model sensitivity introduce execution risks that management must carefully navigate for sustained long-term growth. The company represents an attractive opportunity for investors seeking meaningful exposure to the digital healthcare transformation trend in the United States.

  • Topicus (V:TOI)

    Topicus.com Inc. is a Canadian technology company operating vertical market software businesses that serve specialized industries across multiple sectors globally. Founded in 2020 and headquartered in Toronto, Canada, Topicus provides mission-critical software solutions to healthcare, education, and professional services sectors worldwide. The company focuses on acquiring, developing, and managing software companies serving niche markets with high switching costs and recurring revenue models for sustainable growth.

    Topicus operates through a decentralized model where acquired companies maintain operational independence while benefiting from capital allocation expertise and best practices sharing. The company primarily targets small to medium-sized software businesses in Europe and international markets outside North America for consolidation opportunities. With continued digitalization of specialized industries, Topicus is well-positioned to capitalize on growth opportunities in the fragmented vertical market software landscape globally.

    Topicus financial statements

    Analysts recommendation: 2.3

    Financial Health

    • Return on assets (ROA): 7.15%
    • Return on equity (ROE): 8.02%
    • Return on investment (ROI): 15.6%

    Profitability

    • Gross margin: 36.27%
    • Operating margin: 15.34%
    • Net profit margin: 1.76%

    Growth

    • EPS (past 5 years): 21.3%
    • EPS (current): 0.5
    • EPS estimate (next quarter): 45.8
    • EPS growth (this year): 51.6%
    • EPS growth (next year): 14.2%
    • EPS growth (next 5 years): 16.8%
    • EPS growth (quarter-over-quarter): 19.4%
    • Sales growth (past 5 years): 24.6%
    • Sales growth (quarter-over-quarter): 24.2%

    💡 Why invest in Topicus?

    Topicus presents fundamental strengths that position it well for investors seeking stable returns and growth prospects in software:

    • Niche Vertical Specialization: Topicus targets vertical software markets with high switching costs and recurring revenue, providing defensive business characteristics and predictable cash flow generation from specialized industries worldwide.
    • Proven Acquisition Expertise: The company leverages experienced management team`s track record in identifying, acquiring, and integrating vertical market software businesses while maintaining operational excellence and growth momentum globally.
    • Decentralized Operating Model: Topicus maintains a hands-off approach that preserves entrepreneurial culture and domain expertise within acquired companies while providing capital and strategic guidance for sustainable growth and value creation.
    • European Expansion Strategy: The company focuses on European and international markets outside North America, accessing fragmented software markets with significant consolidation opportunities and less competition from larger acquirers worldwide.

    🐌 Key considerations before investing in Topicus

    However, investors should consider challenges facing Topicus that could impact future performance and investment returns:

    • Acquisition Valuation Pressure: Increasing competition for quality software assets has driven up acquisition multiples, potentially reducing future returns and making it challenging to find attractively priced acquisition targets in markets.
    • Portfolio Integration Risk: Successfully managing a diverse portfolio of acquired companies requires exceptional operational capabilities, and integration failures could negatively impact overall performance and growth trajectory for the business.
    • Geographic Concentration Exposure: Heavy focus on European markets creates geographic concentration exposure and risk to regional economic conditions, regulatory changes, and currency fluctuation impacts on financial performance globally.
    • Capital Allocation Dependency: The company`s success depends heavily on management`s ability to continuously identify and execute profitable acquisitions while maintaining disciplined capital allocation and avoiding destructive deals in the sector.

    Final thoughts on Topicus

    Topicus offers compelling opportunities for investors seeking exposure to vertical market software consolidation through its proven acquisition expertise and decentralized operating model worldwide. The company is well-positioned to capitalize on consolidation opportunities in fragmented software markets across Europe and international regions for long-term growth and value creation. However, integration risks and acquisition valuation pressures require careful evaluation before making investment decisions in Topicus shares for long-term investors.

  • Merit Medical Systems (NYSE:MMSI)

    Merit Medical Systems is a global manufacturer and distributor of medical devices used in interventional, diagnostic, and therapeutic procedures worldwide. Founded in 1987 and headquartered in South Jordan, Utah, the company has expanded its portfolio and reach to become a key player in medical technology. Over the years, Merit Medical has built a strong reputation for innovation and quality manufacturing in the interventional medicine space across global markets.

    The company develops and supplies medical products including catheters, guide wires, embolotherapy devices, and hemostasis management tools for minimally invasive procedures. Merit Medical serves hospitals, healthcare providers, and specialty clinics worldwide, emphasizing innovation and high-quality manufacturing to improve patient outcomes in cardiovascular procedures. Its commitment to advancing minimally invasive procedures has positioned it as a leader in interventional medicine across diverse medical specialties worldwide.

    Merit Medical Systems financial statements

    Analysts recommendation: 1.36

    Financial Health

    • Return on assets (ROA): 4.28%
    • Return on equity (ROE): 8.3%
    • Return on investment (ROI): 5.06%

    Profitability

    • Gross margin: 48.47%
    • Operating margin: 11.1%
    • Net profit margin: 8.02%

    Growth

    • EPS (past 5 years): 83.71%
    • EPS (current): 1.95
    • EPS estimate (next quarter): 0.95
    • EPS growth (this year): -4.2%
    • EPS growth (next year): 7.48%
    • EPS growth (next 5 years): 8.17%
    • EPS growth (quarter-over-quarter): -3.06%
    • Sales growth (past 5 years): 6.38%
    • Sales growth (quarter-over-quarter): 13%

    💡 Why invest in Merit Medical Systems?

    Merit Medical Systems presents fundamental strengths for investors seeking stable returns and growth prospects in medical devices:

    • Interventional Device Focus: Merit Medical specializes in interventional medical devices including catheters, guide wires, and embolotherapy products that enable minimally invasive procedures, benefiting from growing demand in healthcare markets.
    • Product Innovation Investment: The company invests heavily in R&D to develop innovative medical devices and technologies, maintaining competitive advantages through continuous product improvements and new introductions in medical sector.
    • Global Distribution Network: Merit Medical operates worldwide with manufacturing facilities and distribution networks across multiple continents, providing access to growing international healthcare markets and geographic diversification worldwide.
    • Recurring Revenue Streams: The company generates stable revenue streams through disposable medical devices and consumable products that require regular replacement, creating predictable demand from healthcare providers across global markets.

    🐌 Key considerations before investing in Merit Medical Systems

    However, investors should consider challenges facing Merit Medical Systems in its competitive medical device market landscape:

    • Regulatory Approval Burdens: Merit Medical operates in heavily regulated markets requiring FDA approvals and international certifications, creating lengthy development timelines and significant compliance costs for medical devices globally.
    • Medical Device Competition: The medical device industry faces intense competition from established healthcare giants and innovative startups, pressuring margins and requiring continuous R&D investments to maintain market position worldwide.
    • Healthcare Spending Constraints: The company`s performance depends on healthcare capital expenditures and procedure volumes, making it vulnerable to budget constraints, reimbursement changes, and economic downturns affecting hospital spending.
    • Product Lifecycle Management: Medical devices face finite product lifecycles and require continuous innovation to maintain relevance, creating ongoing R&D costs and risks associated with new product development and market acceptance.

    Final thoughts on Merit Medical Systems

    Merit Medical Systems' specialization in interventional devices and steady product innovation support strong participation in the growing minimally invasive care market worldwide. The company's global distribution network and recurring revenue streams from consumable products enhance resilience across healthcare procedures and markets globally. However, investors should carefully weigh regulatory demands, competitive pressures, and product lifecycle challenges in the medical device sector before investing.

If you want to compare different market caps, you may also like my best mega, large cap healthcare stocks.

For the same market cap but different sectors and themes, take a look at my best mid cap automotive, basic materials, beauty, brokers, construction, consulting, defense, education, energy, financial, industrial, insurance, manufacturing, retail, semiconductor, tech, utility stocks.